Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 3
2003 1
2004 2
2005 4
2006 2
2007 11
2008 11
2009 15
2010 12
2011 11
2012 10
2013 23
2014 14
2015 23
2016 26
2017 35
2018 28
2019 38
2020 54
2021 23
Text availability
Article attribute
Article type
Publication date

Search Results

304 results
Results by year
Filters applied: . Clear all
Page 1
Molecular biomarkers in multiple sclerosis.
Ziemssen T, Akgün K, Brück W. Ziemssen T, et al. J Neuroinflammation. 2019 Dec 23;16(1):272. doi: 10.1186/s12974-019-1674-2. J Neuroinflammation. 2019. PMID: 31870389 Free PMC article. Review.
Optimizing treatment success in multiple sclerosis.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Ziemssen T, et al. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705122 Free PMC article. Review.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: ziemssen t. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Schläger C, Körner H, Krueger M, Vidoli S, Haberl M, Mielke D, Brylla E, Issekutz T, Cabañas C, Nelson PJ, Ziemssen T, Rohde V, Bechmann I, Lodygin D, Odoardi F, Flügel A. Schläger C, et al. Among authors: ziemssen t. Nature. 2016 Feb 18;530(7590):349-53. doi: 10.1038/nature16939. Epub 2016 Feb 10. Nature. 2016. PMID: 26863192
Clinical outcome measures in multiple sclerosis: A review.
Inojosa H, Schriefer D, Ziemssen T. Inojosa H, et al. Among authors: ziemssen t. Autoimmun Rev. 2020 May;19(5):102512. doi: 10.1016/j.autrev.2020.102512. Epub 2020 Mar 12. Autoimmun Rev. 2020. PMID: 32173519 Review.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Naismith RT, et al. Among authors: ziemssen t. Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. Epub 2019 Nov 4. Mult Scler. 2020. PMID: 31680631 Free PMC article.
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group. Naismith RT, et al. Among authors: ziemssen t. CNS Drugs. 2020 Feb;34(2):185-196. doi: 10.1007/s40263-020-00700-0. CNS Drugs. 2020. PMID: 31953790 Free PMC article.
304 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page